“As a leader, it’s important to make sure everyone on your team is engaged and included.”
“Implementing inclusion initiatives can make people more comfortable with addressing bias to move toward a healthier and more productive work environment.”
“Allyship is essential, not just for us as professionals, but also as people to broaden our own perspective.”
As Deloitte’s Chief Inclusion Officer, Teri Cooper leads the organization’s efforts to foster an inclusive culture, reimagining inclusion for the workplace of the future. Diversity and inclusion is a business priority and we showcase how inclusion is an essential component of leadership today.
She also leads the Global Healthcare Sector for Deloitte and am a principal in Deloitte Consulting. For more than two decades working in Life Sciences and Healthcare, she participated in a broad range of strategic advisory services, including creating global business models, product development, regulatory affairs, mergers, marketing, product launches, and reengineering information management processes.
Prior to joining Deloitte Consulting, she worked in the pharmaceutical industry managing clinical development, regulatory affairs, sales and marketing; and I’ve gained a broad range of experience in developing new products and obtaining product licenses in the UK and the U.S.
In addition to consulting work, Teri frequently participates in industry conferences, discussing inclusion in the workplace and evolving healthcare and life sciences trends, including emerging cognitive technologies that promise to transform healthcare significantly. Her perspective on these topics has appeared in the Harvard Business Review, Modern Healthcare, and other publications.
She serves on the Board of City Year NY, which places highly trained young people of all backgrounds full-time in schools as tutors, mentors and role models. Additionally, she is a member of the Board of The Friends of the Patients of the NIH, which provides emotional and financial support to the incredibly brave patients receiving groundbreaking and life-saving treatments at the NIH. She holds a Joint Honors Bachelor of Science degree in chemistry/pharmacology and a PhD in pharmacology from the University of London